EP1531799A1 - Formulations nanoparticulaires comprenant des derives d'un inhibiteur de la hmg coa-reductase ("statines"), nouvelles combinaisons associees et production de ces compositions pharmaceutiques - Google Patents
Formulations nanoparticulaires comprenant des derives d'un inhibiteur de la hmg coa-reductase ("statines"), nouvelles combinaisons associees et production de ces compositions pharmaceutiquesInfo
- Publication number
- EP1531799A1 EP1531799A1 EP03738952A EP03738952A EP1531799A1 EP 1531799 A1 EP1531799 A1 EP 1531799A1 EP 03738952 A EP03738952 A EP 03738952A EP 03738952 A EP03738952 A EP 03738952A EP 1531799 A1 EP1531799 A1 EP 1531799A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- less
- statin
- composition
- ammonium chloride
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38740402P | 2002-06-10 | 2002-06-10 | |
US387404P | 2002-06-10 | ||
PCT/US2003/016206 WO2003103640A1 (fr) | 2002-06-10 | 2003-06-10 | Formulations nanoparticulaires comprenant des derives d'un inhibiteur de la hmg coa-reductase (≤statines≥), nouvelles combinaisons associees et production de ces compositions pharmaceutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1531799A1 true EP1531799A1 (fr) | 2005-05-25 |
Family
ID=29736310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03738952A Withdrawn EP1531799A1 (fr) | 2002-06-10 | 2003-06-10 | Formulations nanoparticulaires comprenant des derives d'un inhibiteur de la hmg coa-reductase ("statines"), nouvelles combinaisons associees et production de ces compositions pharmaceutiques |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1531799A1 (fr) |
JP (1) | JP4831965B2 (fr) |
AU (1) | AU2003245313A1 (fr) |
CA (1) | CA2488499C (fr) |
WO (1) | WO2003103640A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1599468T3 (da) | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
DE10339354A1 (de) * | 2003-08-27 | 2005-04-07 | Beisel, Günther | Mittel zur Behandlung des metabolischen Syndroms |
US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
CA2540984C (fr) | 2003-10-10 | 2011-02-08 | Lifecycle Pharma A/S | Forme de dose solide comprenant un fibrate |
TR201909238T4 (tr) | 2004-03-29 | 2019-07-22 | Wyeth Llc | Multi-vitamin ve mineral besin takviyeleri. |
ES2255426B1 (es) | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
KR20070118224A (ko) * | 2005-01-06 | 2007-12-14 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 칸데사르탄 제제 |
MX2007012778A (es) * | 2005-04-12 | 2008-01-11 | Elan Pharma Int Ltd | Formulaciones de derivados de quinazolina nanoparticuladas. |
EP1894576B1 (fr) * | 2005-06-08 | 2011-05-25 | Kowa Company, Ltd. | Nouvel agent réducteur de triglycéride |
JP5112669B2 (ja) * | 2005-09-30 | 2013-01-09 | 富山化学工業株式会社 | 難溶性薬物のナノ微粒子を含有する水性懸濁液剤 |
BRPI0618455A2 (pt) * | 2005-11-11 | 2011-08-30 | Mochida Pharm Co Ltd | composição de geléia |
GB0523810D0 (en) * | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
JP2009529051A (ja) * | 2006-03-07 | 2009-08-13 | オステオスクリーン アイピー, エルエルシー | HMGCo−Aレダクターゼ阻害剤による骨および軟骨の強化 |
DK2018153T3 (da) | 2006-04-26 | 2012-07-23 | Rosemont Pharmaceuticals Ltd | Flydende orale sammensætninger |
GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
EP2057987B1 (fr) * | 2006-08-30 | 2015-03-04 | Kyushu University, National University Corporation | Composition pharmaceutique contenant une nanoparticule de statine encapsulée |
JP4896220B2 (ja) * | 2007-04-27 | 2012-03-14 | 国立大学法人九州大学 | 肺疾患治療薬 |
PL2200588T3 (pl) | 2007-09-25 | 2019-09-30 | Solubest Ltd. | Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania |
FR2937537A1 (fr) | 2008-10-29 | 2010-04-30 | Centre Nat Rech Scient | Nanoparticules de statine |
TR200904500A2 (tr) | 2009-06-10 | 2009-10-21 | Öner Levent | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
ITFI20120268A1 (it) * | 2012-12-03 | 2014-06-04 | Diopeite Consulting Ltd | Composizioni farmaceutiche per il trattamento dell'obesita' |
WO2015185240A1 (fr) | 2014-06-04 | 2015-12-10 | Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. | Compositions contenant de la simvastatine dans des acides gras polyinsaturés oméga-3 |
EP3242666A1 (fr) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Procédés de traitement de maladies associées au récepteur s1p1 |
JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
WO2019143981A1 (fr) * | 2018-01-19 | 2019-07-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions et méthodes d'administration d'agents pharmaceutiques |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2053000C (fr) * | 1990-10-15 | 1995-08-29 | Michael J. Conder | Preparation biosynthetique de 6(r)-[2-(8(s)-hydroxy-2(s), 6(r)-dimethyl-1,2,6,7,8,8a(r)-hexahydronaphtyl)-ethyl]-4 (r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one triol acide par hydrolyse enzymatique de l'acide lovastatine et utilisa tion d'une enzyme issue de clonostachys compactiuscula |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
DE69309056T2 (de) * | 1992-06-10 | 1997-09-18 | Nanosystems Llc | Oberflaechenmodifizierte nsaid nanopartikeln |
US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
WO1998035666A1 (fr) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Preparation de pastilles de naproxene nanoparticulaire |
JP4693238B2 (ja) * | 1998-06-19 | 2011-06-01 | オバン・エナジー・リミテッド | 水に溶けない化合物のサブミクロン粒子を生成させる方法 |
AU2991700A (en) * | 1999-02-11 | 2000-08-29 | Hollis-Eden Pharmaceuticals, Inc. | Methods for treating viral infections |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
US20020058065A1 (en) * | 2000-09-20 | 2002-05-16 | Pol-Henri Guivarc'h | Insoluble drug particle compositions with improved fasted-fed effects |
AU6294501A (en) * | 2000-09-20 | 2002-04-02 | Rtp Pharma Inc | Spray drying process and compositions of fenofibrate |
US6534088B2 (en) * | 2001-02-22 | 2003-03-18 | Skyepharma Canada Inc. | Fibrate-statin combinations with reduced fed-fasted effects |
GB0119480D0 (en) * | 2001-08-09 | 2001-10-03 | Jagotec Ag | Novel compositions |
ATE419835T1 (de) * | 2002-05-06 | 2009-01-15 | Elan Pharma Int Ltd | Nystatin-nanopartikelzusammensetzungen |
CA2488617A1 (fr) * | 2002-06-10 | 2003-12-18 | Eugene R. Cooper | Preparation de sterols nanoparticulaires et nouvelles combinaisons de sterols |
-
2003
- 2003-06-10 WO PCT/US2003/016206 patent/WO2003103640A1/fr active Application Filing
- 2003-06-10 AU AU2003245313A patent/AU2003245313A1/en not_active Abandoned
- 2003-06-10 CA CA2488499A patent/CA2488499C/fr not_active Expired - Fee Related
- 2003-06-10 JP JP2004510760A patent/JP4831965B2/ja not_active Expired - Fee Related
- 2003-06-10 EP EP03738952A patent/EP1531799A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO03103640A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2488499C (fr) | 2013-03-19 |
WO2003103640A1 (fr) | 2003-12-18 |
CA2488499A1 (fr) | 2003-12-18 |
JP4831965B2 (ja) | 2011-12-07 |
AU2003245313A1 (en) | 2003-12-22 |
JP2005532352A (ja) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7763278B2 (en) | Nanoparticulate polycosanol formulations and novel polycosanol combinations | |
US20110027371A1 (en) | Nanoparticulate statin formulations and novel statin combinations | |
CA2488499C (fr) | Compositions nanoparticulaires comprenant des derives inhibiteurs de la hmg-coa reductase (statines), leurs combinaisons ainsi que la fabrication de ces compositions pharmaceutiques | |
US7927627B2 (en) | Nanoparticulate fibrate formulations | |
CA2487054C (fr) | Preparations de fibrate nanoparticulaire | |
US20040033202A1 (en) | Nanoparticulate sterol formulations and novel sterol combinations | |
US20080213378A1 (en) | Nanoparticulate statin formulations and novel statin combinations | |
AU2006309295A1 (en) | Nanoparticulate acetaminophen formulations | |
JP2006508105A5 (fr) | ||
WO2006069098A1 (fr) | Formulations de la bicalutamide nanoparticulaire | |
US20100221327A1 (en) | Nanoparticulate azelnidipine formulations | |
ZA200410209B (en) | Nanoparticulate fibrate formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041222 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RYDE, TUULA Inventor name: LIVERSIDGE, GARY, G. Inventor name: LIVERSIDGE, ELAINE Inventor name: LINDNER, MARIE Inventor name: CAREY, GRETA Inventor name: HOVEY, DOUGLAS Inventor name: COOPER, EUGENE, R. |
|
17Q | First examination report despatched |
Effective date: 20080424 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140103 |